Silmitasertib (CX-4945; CX4945; CX 4945) is a potent, selective, orally bioavailable small-molecule inhibitor of CK2 (casein kinase 2) with potential anticancer activity.

DMAT (CK2 Inhibitor; Casein kinase II Inhibitor) is a novel, potent and selective CK2 (Casein kinase II) inhibitor with an IC50 value of 130 nM.

SU5607 is a novel and potent CK1 inhibitor.

NCC-007 is a novel and potent dual casein kinase Iα (CKIα) and δ (CKIδ) inhibitor.

LH846 is a novel and potent inhibitor of casein kinase.

Quinalizarin is a potent, ATP-competitive, and highly selective (IC50 >1μM against CK1 and 72 other kinases) casein Kinase II (CK2) inhibitor (IC50 = 110 nM), superior to the first-in-class CK2 inhibitor, CX-4945.

Longdaysin is a novel and potent inhibitor of Casein Kinase (CK1α, CK1δ, CDK7) and ERK2 with IC50s of  5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively.

TA-01 is a potent inducer of cardiomyocyte differentiation from human embryonic stem cells following mesoderm induction.